Immuno-Oncology Assay Services

Dr. Martin Kriebel
Group Leader (dep.) Cell- and Molecular Biology

+49 7121 51530-810

E-Mail

Through extensive analysis of a growing number of patient-derived microtumours (PDMs) from diverse cancer types - together with autologous TILs and PBMCs - we have established an advanced, versatile service platform for immuno-oncology (IO) testing of drug candidates, immunotherapies, and combination treatments.

Our offer includes

• Fully customizable fee-for-service studies utilizing PDMs, either alone or co-cultured with autologous immune cells (derived from PBMCs or TILs).
• Measurement of immune cell-mediated cytotoxicity against tumour cells, either alone or in combination with standard-of-care treatments, investigational compounds, immunotherapies, or oncolytic viruses.
• Up to 4D confocal imaging of PDM infiltration by T-lymphocytes.
• Additional Luminex- or Simoa-based cytokine assays, along with DigiWest pathway profiling.
• Full patient consent and FTO to perform commercial service-studies.